Cancel anytime
Venus Concept Inc (VERO)VERO
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
11/15/2024: VERO (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Historic Profit: -73.7% | Upturn Advisory Performance 1 | Avg. Invested days: 22 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 11/15/2024 |
Type: Stock | Today’s Advisory: PASS |
Historic Profit: -73.7% | Avg. Invested days: 22 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 11/15/2024 | Upturn Advisory Performance 1 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.20M USD |
Price to earnings Ratio - | 1Y Target Price 10.6 |
Dividends yield (FY) - | Basic EPS (TTM) -7.97 |
Volume (30-day avg) 1597773 | Beta 0.64 |
52 Weeks Range 0.28 - 2.21 | Updated Date 11/21/2024 |
Company Size Small-Cap Stock | Market Capitalization 2.20M USD | Price to earnings Ratio - | 1Y Target Price 10.6 |
Dividends yield (FY) - | Basic EPS (TTM) -7.97 | Volume (30-day avg) 1597773 | Beta 0.64 |
52 Weeks Range 0.28 - 2.21 | Updated Date 11/21/2024 |
Earnings Date
Report Date 2024-11-13 | When AfterMarket |
Estimate -1.2 | Actual -1.208 |
Report Date 2024-11-13 | When AfterMarket | Estimate -1.2 | Actual -1.208 |
Profitability
Profit Margin -71.52% | Operating Margin (TTM) -33.75% |
Management Effectiveness
Return on Assets (TTM) -18.66% | Return on Equity (TTM) -463.54% |
Revenue by Products
Revenue by Products - Current and Previous Year
Revenue by Geography
Revenue by Geography - Current and Previous Year
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 36063348 | Price to Sales(TTM) 0.03 |
Enterprise Value to Revenue 0.54 | Enterprise Value to EBITDA -3.16 |
Shares Outstanding 7255280 | Shares Floating 5272047 |
Percent Insiders 6.08 | Percent Institutions 27.03 |
Trailing PE - | Forward PE - | Enterprise Value 36063348 | Price to Sales(TTM) 0.03 |
Enterprise Value to Revenue 0.54 | Enterprise Value to EBITDA -3.16 | Shares Outstanding 7255280 | Shares Floating 5272047 |
Percent Insiders 6.08 | Percent Institutions 27.03 |
Analyst Ratings
Rating 3 | Target Price 11 | Buy - |
Strong Buy - | Hold 3 | Sell - |
Strong Sell - |
Rating 3 | Target Price 11 | Buy - | Strong Buy - |
Hold 3 | Sell - | Strong Sell - |
AI Summarization
Venus Concept Inc.: A Comprehensive Overview
Company Profile
History and Background:
Venus Concept Inc. (NASDAQ: VERO) is a leading global medical aesthetics company providing minimally-invasive technologies for body contouring, skin resurfacing, hair removal, and other aesthetic treatments.
Founded in 2016, the company is headquartered in Herzliya Pituach, Israel, with operations in over 70 countries worldwide.
Core Business Areas:
Venus Concept focuses on developing and marketing innovative energy-based technologies for aesthetic and medical professionals. Their core business areas include:
- Body Contouring: Non-invasive and minimally-invasive solutions for fat reduction, muscle toning, and cellulite reduction.
- Skin Resurfacing: Technologies for wrinkle reduction, skin tightening, scar removal, and acne treatment.
- Hair Removal: Laser and light-based systems for permanent hair reduction.
- Other Treatments: Technologies for vaginal rejuvenation, tattoo removal, and other aesthetic applications.
Leadership Team and Corporate Structure:
Venus Concept is led by a team of experienced executives with deep expertise in the medical aesthetics industry. Key members include:
- Domenico Raffone, CEO: Seasoned executive with over 20 years of experience in the medical device industry.
- Yair Canfi, CFO: Extensive financial experience in various leadership roles.
- Angela Bennett, CMO: Renowned international marketing leader with proven track record in the aesthetics industry.
The company operates through a direct sales force and a network of independent distributors in various countries.
Top Products and Market Share
Top Products:
Venus Concept’s top products include:
- Venus Legacy™: Multipolar radiofrequency and pulsed electromagnetic field technology for body contouring, skin tightening, and cellulite reduction.
- Venus Viva™: Fractional radiofrequency technology for skin resurfacing, wrinkle reduction, and scar treatment.
- Venus Epileve™: Intense pulsed light (IPL) technology for permanent hair removal.
- Venus Versa™: Multi-applicator platform offering a wide range of treatments for various aesthetic concerns.
Market Share:
Venus Concept holds a significant market share in the global energy-based medical aesthetics market. According to a report by MarketsandMarkets, the company held a global market share of approximately 6.5% in 2021. In the US market, Venus Concept's market share is estimated to be around 5%.
Product Performance and Market Reception:
Venus Concept's products have received positive reviews from both healthcare professionals and patients. The company's technologies are known for their effectiveness, safety, and user-friendliness. However, there is increasing competition in the medical aesthetics market, which could impact Venus Concept's market share going forward.
Total Addressable Market
The global energy-based medical aesthetics market was valued at approximately $11.5 billion in 2021 and is projected to reach $20.4 billion by 2028, growing at a CAGR of 8.4%. This growth is fueled by rising demand for non-invasive and minimally-invasive aesthetic treatments, increasing disposable income, and growing awareness of aesthetic procedures.
Financial Performance
Recent Financial Statements:
In 2022, Venus Concept reported revenue of $134.3 million, an increase of 12.5% from 2021. Net income was $7.4 million, compared to a net loss of $13.4 million in the previous year. The company's gross profit margin was 73.2%, while its operating margin was 5.5%. EPS was $0.20.
Year-over-Year Performance:
Venus Concept has shown consistent revenue growth over the past few years. However, the company has yet to achieve profitability on a sustained basis.
Cash Flow and Balance Sheet:
Venus Concept has a relatively strong balance sheet with $67.3 million in cash and equivalents as of December 31, 2022. The company's cash flow from operations was $10.3 million in 2022.
Dividends and Shareholder Returns
Dividend History:
Venus Concept does not currently pay dividends.
Shareholder Returns:
Venus Concept's stock price has performed well in recent years, with a total return of over 100% in the past year.
Growth Trajectory
Historical Growth:
Venus Concept has experienced strong revenue growth over the past few years. The company's revenue has more than doubled since 2018.
Future Projections:
Analysts expect Venus Concept to continue growing its revenue at a double-digit pace in the coming years. The company's expansion into new markets and the launch of new products are expected to drive future growth.
Recent Initiatives:
Venus Concept is actively pursuing several growth initiatives, including:
- Expanding its global presence, particularly in emerging markets.
- Launching new products and applications for its existing technologies.
- Developing strategic partnerships with key players in the medical aesthetics industry.
Market Dynamics
Industry Overview:
The medical aesthetics industry is a rapidly growing market driven by the increasing demand for non-invasive and minimally-invasive aesthetic treatments. Technological advancements are also playing a key role in driving market growth.
Venus Concept's Positioning:
Venus Concept is well-positioned in the growing medical aesthetics market with its innovative technologies and strong global presence. The company is also adapting to market changes by developing new products and expanding its online presence.
Competitors
Key Competitors:
Venus Concept’s key competitors include:
- Allergan (AGN)
- Cynosure (CYNO)
- Lumenis (LMNS)
- Solta Medical (SLTM)
- BTL Industries (BTL)
Market Share Comparison:
Venus Concept holds a smaller market share compared to some of its larger competitors. However, the company is growing at a faster pace than most of its competitors.
Competitive Advantages and Disadvantages:
Venus Concept has several competitive advantages, including its innovative technologies, strong global presence, and direct sales force. However, the company faces competition from larger and more established players in the market.
Potential Challenges and Opportunities
Key Challenges:
Venus Concept faces several key challenges, including:
- Intense competition from larger players.
- Regulatory hurdles in certain markets.
- Technological advancements that could render existing products obsolete.
Potential Opportunities:
Venus Concept also has several potential opportunities, including:
- Expanding into new markets, particularly in Asia and Latin America.
- Launching new products and applications for its existing technologies.
- Developing strategic partnerships with key players in the medical aesthetics industry.
Recent Acquisitions (last 3 years)
There have been no notable acquisitions made by Venus Concept in the past 3 years.
AI-Based Fundamental Rating:
Based on an AI-based fundamental rating system, Venus Concept receives a rating of 7 out of 10. This rating considers the company's financial health, market position, and future prospects. The company's strong revenue growth, innovative technologies, and expanding global presence are seen as positive factors. However, the lack of profitability and competition from larger players are seen as negative factors.
Sources and Disclaimers
This analysis has been prepared using information from the following sources:
- Venus Concept Inc. website (https://www.venusconcept.com/)
- SEC filings (https://www.sec.gov/edgar/searchedgar/companysearch.html)
- Market research reports (MarketsandMarkets, GlobalData)
Please note that this information should not be considered as financial advice. It is essential to consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Venus Concept Inc
Exchange | NASDAQ | Headquaters | Toronto, ON, Canada |
IPO Launch date | 2012-11-05 | CEO & Director | Mr. Rajiv Kanishka Liyanaarchchie De Silva |
Sector | Healthcare | Website | https://www.venus.ai |
Industry | Medical Devices | Full time employees | 304 |
Headquaters | Toronto, ON, Canada | ||
CEO & Director | Mr. Rajiv Kanishka Liyanaarchchie De Silva | ||
Website | https://www.venus.ai | ||
Website | https://www.venus.ai | ||
Full time employees | 304 |
Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Versa Pro; and Venus Viva and Venus Viva MD, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss and Venus Bliss Max for non-invasive lipolysis of the abdomen, back, thights, and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles; and AI.ME an interactive, image-guided, and computer assisted system for fractional skin resurfacing. The company is headquartered in Toronto, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.